Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Century Therapeutics, Inc. - Common Stock
(NQ:
IPSC
)
0.5304
-0.0266 (-4.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Century Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Analyst Ratings for Century Therapeutics
April 13, 2023
Via
Benzinga
Century Therapeutics Announces Leadership Changes
April 12, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics's Return On Capital Employed Overview
March 20, 2023
Via
Benzinga
Where Century Therapeutics Stands With Analysts
March 16, 2023
Via
Benzinga
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
March 16, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the AACR Annual Meeting 2023
March 15, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
8 Analysts Have This to Say About Century Therapeutics
January 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
December 27, 2022
Via
Benzinga
Century Therapeutics to Present at Upcoming Investor Conferences
February 21, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
February 08, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
February 01, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Stocks That Hit 52-Week Lows On Thursday
January 19, 2023
On Thursday, 29 stocks made new 52-week lows.
Via
Benzinga
5 Health Care Stocks That Are Diving - And May Rally
January 19, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 12, 2023
On Thursday, 13 stocks hit new 52-week lows.
Via
Benzinga
Top 5 Health Care Stocks That May Surge
January 10, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
January 06, 2023
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.
Via
InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
January 06, 2023
Via
Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
January 05, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
December 20, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
November 11, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
November 02, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
Century Therapeutics to Present at the SITC 37th Annual Meeting
October 05, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
October 03, 2022
From
Century Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.